ライフサイエンスコーパス: transplant outcome

1 risk of transplant or the combined death or transplant outcome.

2 ors other than islet quality that affect the transplant outcome.

3 tion of patients according to their risk for transplant outcome.

4 elsior (CS) solutions on islet isolation and transplant outcome.

5 er or surgeon transplant workload on corneal transplant outcome.

6 ector cells affect alloimmune reactivity and transplant outcome.

7 sociated with a detrimental effect on kidney transplant outcome.

8 oratory variables, to identify predictors of transplant outcome.

9 s for BK virus (BKV) replication may improve transplant outcome.

10 utic agents for the long-term improvement of transplant outcome.

11 ology of DC populations in relation to human transplant outcome.

12 ells in the complex events that affect liver transplant outcome.

13 ing regimen and source of stem cells, affect transplant outcome.

14 to identify indications, complications, and transplant outcome.

15 's would not appear to substantially improve transplant outcome.

16 nisms that are involved in determining islet transplant outcome.

17 matching at the triplet level affects kidney transplant outcome.

18 genetic variability in molecules relevant to transplant outcome.

19 ildren with ALL without compromising overall transplant outcome.

20 ersus-host disease (GVHD) and may compromise transplant outcome.

21 ted to improve unrelated donor selection and transplant outcome.

22 ne the influence of panresistant bacteria on transplant outcome.

23 to determine the impact of these changes on transplant outcome.

24 d not add substantially to the evaluation of transplant outcome.

25 lantation is an important determinant of the transplant outcome.

26 ient population has the potential to improve transplant outcome.

27 (c-statistics) were performed for models of transplant outcome.

28 D-induced obesity and its negative impact on transplant outcome.

29 hanisms by which these cells influence liver transplant outcome.

30 ng this disease-initiating process to modify transplant outcome.

31 s failing to be consistently associated with transplant outcome.

32 raft loss is not associated with poor second transplant outcome.

33 ry T cells (Tregs) play an important role in transplant outcome.

34 unities to ultimately improve long-term lung transplant outcome.

35 cs are becoming more important in predicting transplant outcome.

36 mpact of preoperative albumin levels on post-transplant outcome.

37 are therefore needed for improving long-term transplant outcome.

38 ere independently associated with successful transplant outcome.

39 an is not stopped, thus resulting in optimal transplant outcomes.

40 ould potentially lead to improved islet cell transplant outcomes.

41 resistance, and risk prediction of pediatric transplant outcomes.

42 donor smoking history in relation to age on transplant outcomes.

43 ith AKI are often discarded for fear of poor transplant outcomes.

44 es may interact to negatively influence lung transplant outcomes.

45 Little is known about their post-transplant outcomes.

46 ssociation of CAV2 gene variants with kidney transplant outcomes.

47 , and high levels correlated with poor islet transplant outcomes.

48 tment for known risk factors associated with transplant outcomes.

49 an important goal to improve long-term lung-transplant outcomes.

50 ransplantation has been associated with poor transplant outcomes.

51 e, SOTR are at risk of nonadherence and poor transplant outcomes.

52 between increasing center volume and cardiac transplant outcomes.

53 ditioning may not be required for successful transplant outcomes.

54 sensitization and adversely impacting islet transplant outcomes.

55 e impact of donor aged 70 years and older on transplant outcomes.

56 Vitamin A supplementation might improve transplant outcomes.

57 MF) is associated with good short-term renal transplant outcomes.

58 cal to the informed interpretation of kidney transplant outcomes.

59 environmental causes of disparities in renal transplant outcomes.

60 vidence shows their association with adverse transplant outcomes.

61 ed eplet loads affect antibody responses and transplant outcomes.

62 independent modifiable risk factor for renal transplant outcomes.

63 en virtual and actual crossmatch results and transplant outcomes.

64 toimmune disorder had no positive effects on transplant outcomes.

65 gens are important determinants of long-term transplant outcomes.

66 cant impact of these infections on the other transplant outcomes.

67 invasive procedures and improves patient or transplant outcomes.

68 week (UNOS-DGF), associates with poor kidney transplant outcomes.

69 urce of HO-1 and higher levels improve renal transplant outcomes.

70 oholic steatohepatitis (NASH) with good post-transplant outcomes.

71 esents a novel clinical target for improving transplant outcomes.

72 (HSPC) engraftment is paramount to improving transplant outcomes.

73 ues to lag behind the progress in short-term transplant outcomes.

74 t immunosuppression is known to affect renal transplant outcomes.

75 preservation fluids for liver allografts on transplant outcomes.

76 tin (EPO) is associated with improved kidney transplant outcomes.

77 transplantation is essential for successful transplant outcomes.

78 of antibody and B cells on acute and chronic transplant outcomes.

79 ion in a preparation may contribute to islet transplant outcomes.

80 h LN, income levels did not predict risk for transplant outcomes.

81 fact associated with adverse recipient post-transplant outcomes.

82 dels for reporting program-specific pancreas transplant outcomes.

83 while maintaining efficacy may improve renal transplant outcomes.

84 he factors that significantly affected early transplant outcome adversely within 3 months posttranspl

85 dentified a number of factors that influence transplant outcome after deceased heart beating donor ki

86 Imaging investigations and transplant outcomes after genetic testing were collected

87 mobilized peripheral blood (PB), we compared transplant outcomes after PB and BM transplants.

88 actors of sclerosis and its association with transplant outcomes among 977 consecutive patients treat

89 rs for ZIKV infection among organ donors and transplant outcomes among recipients of donors with posi

90 aim of this study was to compare the kidney transplant outcomes among recipients of kidney after pri

91 atching, 16 potential risk factors for heart transplant outcome and 16 potential risk factors for lun

92 lationship between microbial communities and transplant outcome and aid in assessing lung infections.

93 act of these leukocyte-directing proteins on transplant outcome and novel therapeutic approaches for

94 dom includes factors demonstrated to improve transplant outcome and promote equity in organ allocatio

95 ry donor-reactive T cells are detrimental to transplant outcome and that quantifying the frequency of

96 to confirm a relationship between post-heart transplant outcomes and center experience and to determi

97 significantly to the scientific analyses of transplant outcomes and complications and provide import

98 n humans, offering opportunities to optimize transplant outcomes and maximize donor organ utilization

99 urce of organs for transplantation with good transplant outcomes and there is scope for increasing th

100 ere are significant differences in both post-transplant outcomes and time to transplantation between

101 olymorphism in human disease susceptibility, transplant outcome, and donor selection.

102 Humoral sensitization affects transplant outcome, and it is now apparent that human le

103 nd treatment of active CMV infection enhance transplant outcomes, and are the focus of this section.

104 existing literature on age-related changes, transplant outcomes, and complications in the elderly in

105 es that have predictive value for subsequent transplant outcome are presented and discussed.

106 th nondilated forms of CMP, their short-term transplant outcomes are good.

107 Poor second transplant outcomes are identified among patients with p

108 glomerular filtration rate (eGFR) with renal transplant outcomes are limited.

109 In children, poorly HLA-matched LD renal transplant outcomes are not inferior when compared with

110 Improved transplant outcomes are now making UCBT a rival to URD t

111 ary artery disease (Mod-CAD) undergoing lung transplant, outcomes are not well defined.

112 with panresistant P. aeruginosa have similar transplant outcomes as patients with sensitive bacteria

113 The risks for transplant outcomes associated with baseline viral seros

114 onsidered as a possible prognostic factor in transplant outcomes, associated with anxiety, health-rel

115 Transplant outcome at 1-year posttransplant was similar

116 this policy on racial disparities in kidney transplant outcomes at 5 years.

117 e Index (KDPI), a metric intended to predict transplant outcomes based on donor characteristics but d

118 A similar decision model comparing kidney transplant outcomes before and after the introduction of

119 Proteinuria has been related to kidney transplant outcomes, but there are no information about

120 models were built to examine differences in transplant outcomes by graft type, adjusting for patient

121 that individual HLA loci play in determining transplant outcome can be achieved, and this is a major

122 ts demonstrates that excellent 5-year kidney transplant outcomes can be achieved without CNI drugs, w

123 Transplant outcomes can be optimized by peritransplant T

124 Our objective was to explore how renal transplant outcomes could be predicted by a combined var

125 iopsy analysis is associated with acceptable transplant outcomes for elderly DCD kidneys and may incr

126 differences in access to transplant and post-transplant outcomes for ethnic minority patients in the

127 Transplant outcomes for kidneys scoring from 0 to 4 were

128 nsin (UW) preservation solutions in clinical transplant outcomes for liver, pancreas, and kidney tran

129 dominant factor responsible for worse liver transplant outcomes for minority recipients.

130 This study reports the transplant outcomes for pancreas allografts procured sim

131 to identify additional genetic predictors of transplant outcome/function.

132 e candidate gene for association with kidney transplant outcomes given its proximity to CAV1 and its

133 The effects on transplant outcome (graft and recipient survival) were e

134 ients from the multicenter, prospective Lung Transplant Outcomes Group cohort enrolled between July 2

135 l study, nested within the multi-center Lung Transplant Outcomes Group cohort.

136 n study of the multicenter, prospective Lung Transplant Outcomes Group cohort.

137 and plasma leptin and mortality in 599 Lung Transplant Outcomes Group study participants.

138 pective cohort study of patients in the Lung Transplant Outcomes Group who underwent bilateral lung t

139 tween March 2002 and December 2010 (the Lung Transplant Outcomes Group).

140 sttransplant anemia and its association with transplant outcomes have not been properly studied.

141 the most significant factor predicting poor transplant outcome (hazard ratio for 18-39 and 60+ years

142 as well as the effect of this phenomenon on transplant outcome, however, are vague.

143 s (DSAs) are associated with impaired kidney transplant outcome; however, whether these antibodies in

144 We reviewed transplant outcome in 103 consecutive patients with chil

145 Transplant centers reported on transplant outcome in 1112 patients given PCB grafts thr

146 nt and donor age on immunoresponsiveness and transplant outcome in a uni- and multilateral cohort ana

147 The use of immunonutrients improves transplant outcome in animals treated with short courses

148 e, is a significant predictor of unfavorable transplant outcome in first and second renal transplants

149 ansplant serum albumin concentration on post-transplant outcome in heart transplant recipients.

150 fect of donor age and cold ischaemic time on transplant outcome in kidneys donated after circulatory

151 etic polymorphisms have been associated with transplant outcome in some experimental and clinical stu

152 We compared transplant outcome in uDCD (n = 97) and cDCD (n = 1441).

153 Here, we analyzed the transplant outcomes in 335 NM receiving islets from huma

154 We compared apheresis utilization and transplant outcomes in ABOi, XM, and combined ABOi-XM re

155 ts, but the influence of humoral immunity on transplant outcomes in children is not well understood.

156 ditioning intensity are warranted to improve transplant outcomes in MDS.

157 factors of CMV disease and its impact on SPK transplant outcomes in recipients all receiving a consis

158 donor (D)/recipient (R) serostatus on kidney transplant outcomes in recipients who received CMV proph

159 ncome and racial/ethnic disparities on renal transplant outcomes in recipients with lupus nephritis (

160 emonstrate that mHGF markedly improves islet transplant outcomes in the highest preclinical species e

161 rapy has the potential to improve DCD kidney transplant outcomes in the human setting.

162 ntibody induction therapy for 6-month kidney transplant outcomes in the modern immunosuppression era.

163 stigated the effect of smoking on postkidney transplant outcomes in the United States Renal Data Syst

164 Information about short- and long-term transplant outcomes in this ethnic group is limited, alt

165 is in vitro and significantly improved islet transplant outcomes in vivo.

166 the first time poorer waitlist and postliver transplant outcomes in young adults ages 18 to 24 years

167 Avenues being pursued to improve transplant outcomes include natural killer cell immunoth

168 ased risk models associated with the risk of transplant outcomes including graft-versus-host disease

169 Here, we highlight ways in which transplant outcome is determined by unique immunological

170 nknown but the risks seem low, and long-term transplant outcome is excellent.

171 ct of this information on organ donation and transplant outcome is not well documented.

172 etween severity of chronic kidney injury and transplant outcome is similar for DCD and DBD kidneys.

173 esence within solid organ allografts affects transplant outcomes is not known.

174 candidates and their impact on waitlist and transplant outcomes is not known.

175 ctors in modulating alloimmune responses and transplant outcomes is only now beginning to emerge.

176 r, the impact of some of these infections on transplant outcomes is still unclear.

177 sensitive solid-phase assays (SPAs) on renal transplant outcomes is unclear.

178 y mass index (BMI) on pediatric-donor kidney transplant outcomes is unclear.

179 ristics ("nurture") on deceased-donor kidney transplant outcomes is unknown.

180 ) cells in hematopoietic stem cell grafts to transplant outcomes is warranted.

181 Improved early kidney transplant outcomes limit the contemporary utility of st

182 ctive comparison of treatment-related kidney transplant outcomes may be facilitated by multivariable

183 cal care in the areas of donor use, clinical transplant outcomes, mechanisms of rejection, infectious

184 ating this into clinical practise to improve transplant outcome, much focus has been placed on trying

185 ia donors and the impact of donor factors on transplant outcomes must therefore be considered.

186 I and II), is increasing; and its effect on transplant outcomes needs evaluation.

187 nor and recipient is associated with optimal transplant outcome, new information suggests that not ev

188 ialysis has been associated with poor kidney transplant outcome, no data about this association exist

189 re the main determinants of long-term kidney transplant outcome; nonimmunologic factors in isolation

190 pectively compared the transplantability and transplant outcome of two consecutive patient population

191 aluable to determine the effect on long-term transplant outcomes of diabetes in cornea donors.

192 This study compares transplant outcomes of SRL-based induction immunosuppres

193 or and recipient had a significant effect on transplant outcome: older age was associated with increa

194 sed donor recovery, improvement of long-term transplant outcomes, optimization of immune monitoring,

195 Transplant outcomes remain robust, with continuously imp

196 Long-term kidney transplant outcomes remain suboptimal, delineating an un

197 A common lament is that long-term kidney transplant outcomes remain the same despite improvements

198 ease, with its associated morbidity and poor transplant outcome, represents a serious threat to trans

199 PURPOSE OF REVIEW: Successful transplant outcomes require optimal patient selection an

200 phisms and minor histocompatibility genes in transplant outcome requires investigation.

201 In conclusion, racial disparities in kidney transplant outcomes seem to persist even in a universal

202 T cells efficiently and to improve long-term transplant outcomes significantly.

203 m RDs who are not HLA-matched siblings, with transplant outcomes similar to patients with MSD grafts.

204 fied to determine how biological age impacts transplant outcome, such as age-related fibrosis or tubu

205 fied to determine how biological age impacts transplant outcome, such as age-related fibrosis or tubu

206 Because colonized organs have worse transplant outcome than sterile organs, we tested the in

207 It is associated with transplant outcomes that are equivalent to those with UW

208 as the MHC region as well as genomewide for transplant outcomes that span all solid organs, such as

209 erstand a differential effect of SES on post-transplant outcomes that was not seen during LVAD suppor

210 tem heparin administration improve DCD liver transplant outcomes, thus allowing for the most effectiv

211 ic murine model of diabetes by comparing the transplant outcomes to that of islets transplanted intra

212 e purpose of this study was to analyze renal transplant outcomes using this source of cadaveric (CAD)

213 Islet transplant outcome was analyzed in 59 consecutive pancre

214 n lymphatic or blood vessel distribution and transplant outcome was analyzed.

215 Transplant outcome was assessed 60 days postgrafting by

216 Importantly, the predictive power for poorer transplant outcome was comparable for all definitions of

217 Transplant outcome was similar in recipients of organs f

218 This comprehensive analysis of transplant outcomes was undertaken to inform development

219 evelop a donor selection strategy to improve transplant outcome, we compared the contribution of thes

220 ence of B. cepacia complex genomovar type on transplant outcome, we undertook a retrospective study i

221 ith ESRD affects time to transplantation and transplant outcomes, we retrospectively analyzed 3782 ma

222 Donor factors potentially influencing transplant outcome were investigated using Cox regressio

223 tcome and 16 potential risk factors for lung transplant outcome were subjected to multivariate analys

224 Lipid levels, safety, and post-transplant outcomes were also assessed as secondary end

225 Post-transplant outcomes were analyzed pertaining to patient

226 Transplant outcomes were compared in stone formers and c

227 ed if their original consent forms to report transplant outcomes were not signed, if consent was with

228 The best transplant outcomes were observed in pts with lymphoid m

229 roscopic liver findings, and procurement and transplant outcomes were reviewed.

230 Kidney transplant outcomes were worse, however, for patients wi

231 nt studies have documented an improvement in transplant outcome when organs are preserved through pul

232 r (LD)-related risk factors affecting kidney transplant outcome will allow better donor selection and

233 Mandatory continuous monitoring of early transplant outcome with centralized oversight was introd

234 ion-controlled 1-g MMF results in comparable transplant outcomes with less GI toxicity during the fir

235 ion and sirolimus provides comparable 1-year transplant outcomes, with significantly better renal fun

236 se transplant model, we investigated whether transplant outcome would result in changes in the propor

237 ricans and that racial disparities in kidney transplant outcomes would be less pronounced among patie

238 which T cells are removed, it is likely that transplant outcomes would depend on which technique is u